mitomycin has been researched along with Response Evaluation Criteria in Solid Tumors in 2 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Response Evaluation Criteria in Solid Tumors: An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitomycin C (MMC) has potent cytotoxicity but cumulative toxicity limits widespread use." | 2.80 | Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. ( Amitay, Y; Berger, R; Gabizon, AA; Golan, T; Grenader, T; La-Beck, NM; Ohana, P; Shmeeda, H; Tahover, E, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rovers, KP | 1 |
| Bakkers, C | 1 |
| Nienhuijs, SW | 1 |
| Burger, JWA | 1 |
| Creemers, GM | 1 |
| Thijs, AMJ | 1 |
| Brandt-Kerkhof, ARM | 1 |
| Madsen, EVE | 1 |
| van Meerten, E | 1 |
| Tuynman, JB | 1 |
| Kusters, M | 1 |
| Versteeg, KS | 1 |
| Aalbers, AGJ | 1 |
| Kok, NFM | 1 |
| Buffart, TE | 1 |
| Wiezer, MJ | 1 |
| Boerma, D | 1 |
| Los, M | 1 |
| de Reuver, PR | 1 |
| Bremers, AJA | 1 |
| Verheul, HMW | 1 |
| Kruijff, S | 1 |
| de Groot, DJA | 1 |
| Witkamp, AJ | 1 |
| van Grevenstein, WMU | 1 |
| Koopman, M | 1 |
| Nederend, J | 1 |
| Lahaye, MJ | 1 |
| Kranenburg, O | 1 |
| Fijneman, RJA | 1 |
| van 't Erve, I | 1 |
| Snaebjornsson, P | 1 |
| Hemmer, PHJ | 1 |
| Dijkgraaf, MGW | 1 |
| Punt, CJA | 1 |
| Tanis, PJ | 1 |
| de Hingh, IHJT | 1 |
| Golan, T | 1 |
| Grenader, T | 1 |
| Ohana, P | 1 |
| Amitay, Y | 1 |
| Shmeeda, H | 1 |
| La-Beck, NM | 1 |
| Tahover, E | 1 |
| Berger, R | 1 |
| Gabizon, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951] | Phase 2/Phase 3 | 358 participants (Anticipated) | Interventional | 2017-06-01 | Recruiting | ||
| An Open Phase 1B Study for Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Oxaliplatin-based Chemotherapy in Patients With Gastro-intestinal Malignancies[NCT04729205] | Phase 1 | 9 participants (Actual) | Interventional | 2021-01-13 | Terminated (stopped due to Investigational drug not available) | ||
| A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.[NCT01705002] | Phase 1 | 88 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for mitomycin and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cap | 2021 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Fatigue; Female; Humans; Liposomes; Male; Maximum | 2015 |